{
    "2019-02-14": [
        [
            {
                "time": "2023-03-15",
                "original_text": "Incyte (INCY) Q4 Earnings Miss Estimates, Revenues Beat",
                "features": {
                    "keywords": [
                        "Incyte",
                        "Q4",
                        "Earnings Miss",
                        "Revenues Beat"
                    ],
                    "sentiment_score": -0.3,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "The Zacks Analyst Blog Highlights: ExxonMobil, Merck, Danaher, Novartis and Expedia",
                "features": {
                    "keywords": [
                        "Zacks Analyst Blog",
                        "ExxonMobil",
                        "Merck",
                        "Danaher",
                        "Novartis",
                        "Expedia"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "energy",
                        "healthcare",
                        "industrials",
                        "travel"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",
                "features": {
                    "keywords": [
                        "Vanda",
                        "Q4 Results",
                        "Inovio",
                        "Debt Offering",
                        "Caladrius",
                        "Diabetes Drug",
                        "Flunks",
                        "Mid-Stage Trial"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2023-03-15",
                "original_text": "J&J and Novartis back cancer geneticistâ€™s immunotherapy start-up",
                "features": {
                    "keywords": [
                        "J&J",
                        "Novartis",
                        "cancer",
                        "geneticist",
                        "immunotherapy",
                        "start-up"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotech",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}